LNTH · Lantheus Holdings Inc.
AI read · Good for LNTH
The AI's read
FDA approved Tauklarify, a Tau PET radiodiagnostic for adults being evaluated for Alzheimer’s, giving Lantheus a cleared commercial product. That turns a development-stage asset into a revenue-bearing franchise and strengthens pharma partnerships. The market barely reacted. LNTH is essentially flat at -0.02% and RSI 58, so the approval does not look priced in yet. We lean bullish: approval creates real commercial optionality, but adoption, reimbursement, and launch execution will set timing. Expect upside if Lantheus publishes clear commercialization plans and partner demand confirms take-up.